| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a305f832ebc74c923043715dd06e42a0 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-30
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-21
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-519
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-33
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4439
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2020-04-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_859aaf4ab4e2e736c09b65eec43d7ca4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef66f98250aa9c284aa55292d888f1c7 |
| publicationDate |
2020-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2020222668-A1 |
| titleOfInvention |
Rank pathway inhibitors in combination with cdk inhibitors |
| abstract |
Provided herein are pharmaceutical compositions comprising i) a RANK pathway inhibitor in combination with ii) a CDK inhibitor, and related methods. Provided herein are methods of increasing or restoring a responsiveness or sensitivity of a cancer cell to treatment with a CDK inhibitor and methods of treating a subject with a resistance or reduced sensitivity to treatment with a CDK inhibitor. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022237856-A1 |
| priorityDate |
2019-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |